Somewhat Positive Press Coverage Somewhat Unlikely to Impact Chimerix (CMRX) Stock Price

Media coverage about Chimerix (NASDAQ:CMRX) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chimerix earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.2748924084521 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

Several analysts recently issued reports on CMRX shares. Zacks Investment Research lowered shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Monday, January 22nd. JPMorgan Chase lowered shares of Chimerix from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. HC Wainwright started coverage on shares of Chimerix in a research report on Friday, February 2nd. They set a “buy” rating and a $10.00 price target on the stock. Cowen reiterated a “hold” rating and set a $6.00 price target on shares of Chimerix in a research report on Thursday, March 1st. Finally, BidaskClub upgraded shares of Chimerix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $7.06.

Shares of NASDAQ CMRX traded down $0.11 during trading hours on Friday, hitting $4.83. 168,775 shares of the stock were exchanged, compared to its average volume of 137,572. The firm has a market capitalization of $230.16, a price-to-earnings ratio of -3.20 and a beta of 1.25. Chimerix has a 1-year low of $4.17 and a 1-year high of $6.24.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.07. The business had revenue of $1.84 million for the quarter, compared to analyst estimates of $0.83 million. Chimerix had a negative net margin of 1,579.53% and a negative return on equity of 29.22%. equities research analysts predict that Chimerix will post -1.78 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-chimerix-cmrx-stock-price.html.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Insider Buying and Selling by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply